Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
eye diseases | D005128 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
enspryng | Biologic Licensing Application | 2023-07-12 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
neuromyelitis optica | EFO_0004256 | D009471 | G36.0 |
Expiration | Code | ||
---|---|---|---|
satralizumab, Enspryng, Genentech, Inc. | |||
2027-08-14 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | — | — | — | — | 1 |
Cerebral infarction | D002544 | — | I63 | 1 | — | — | — | — | 1 |
Brain ischemia | D002545 | EFO_0003883 | I67.82 | 1 | — | — | — | — | 1 |
Drug common name | Satralizumab |
INN | satralizumab |
Description | Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1535963-91-7 |
RxCUI | — |
ChEMBL ID | CHEMBL3833307 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB15762 |
UNII ID | YB18NF020M (ChemIDplus, GSRS) |